The business of Huikang and Weining Health, which was announced to be reorganized, suddenly fell through today.
After trading on July 23, Venture Huikang issued a notice saying that after communicating with the relevant parties on the original transaction core plan, the two sides of the transaction could not agree on the core terms. After careful study, the company decided to stop planning this major asset restructuring, and the company's shares resumed trading on Monday, July 26, 2021.
Earlier, the company announced that the company's shares were suspended from trading on July 19, 2021 because the company and Weining Health planned for Weining Health to merge Venture Huikang by issuing A shares to all shareholders of Venture Huikang.
Some netizens said in the stock bar: what do you mean?
Previously, there was a view that if the restructuring is successful, there will be a new leader in the medical information industry.
According to the current competition pattern, Weining Health and Entrepreneurship Huikang ranked first and third in the industry respectively, with a small gap with the second Neusoft Group.
Data show that in 2020, the top five market share of the hospital core management system totaled 39%, of which Weining Health ranked first with a market share of 12.4%, and Huikang ranked third with a market share of 6.5%. After the merger of the two companies, it can reach 18.9%, widening the gap with the second Neusoft Group (9.7%).
In the electronic medical record system, Weining Health occupies the second place with a market share of 12%, and Huikang City, a startup, ranks fifth with a share of 7.2%. After the merger, it will reach 19.2%, surpassing the current first place, Jiahe Meikang (18.6%).
In the capital market, Weining Health currently has a market capitalization of about 35 billion yuan, while Huikang, a startup, has a market capitalization of about 13 billion yuan. Before the merger announcement, the share prices of the two were mediocre.
Among them, Weining Health's share price reached a nearly five-year high of 27.42 yuan per share in July last year, but it has weakened since then, trading at 16.48 yuan as of July 16 before the suspension. The stock price of Huikang, a startup, moved in a similar way, closing at 8.63 yuan per share on July 16 before the suspension, nearly halving its market capitalization compared with its peak.